Jacqueline Garcia, MD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jacqueline Garcia, MD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Jacqueline Garcia, MD: 5 sponsored US clinical trials, 1 recruiting.
Jacqueline Garcia, MD sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), with 1 trials.
Upper-quartile sponsor footprint
Jacqueline Garcia, MD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
NCT07148180
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
NCT05455294
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
NCT03613532
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
NCT07439211
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03125239
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
What is open in the Jacqueline Garcia, MD pipeline
1 recruiting of 5 indexed (20% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable) (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jacqueline Garcia, MD: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Jacqueline Garcia, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Jacqueline Garcia, MD page
5 registered trials is a research-attention snapshot, not an endorsement of Jacqueline Garcia, MD or any single study.
- 1 of Jacqueline Garcia, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable) is the condition Jacqueline Garcia, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jacqueline Garcia, MD pipeline card: 5 registered trials from official public datasets.Report a data error.